DPP-4 Inhibition and the Path to Clinical Proof
Frontiers in Endocrinology, 2019 In the 1990s it was discovered that the enzyme dipeptidyl peptidase-4 (DPP-4) inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Bo Ahrén
doaj +1 more source
Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
Фармация и фармакология (Пятигорск), 2023 Modern requirements for the treatment of type 2 diabetes mellitus (DM2) include not only achieving a glycemic control, but also reducing the risk of developing cardiovascular complications.
D. V. Kurkin +9 more
doaj +1 more source
3D-QSAR-based pharmacophore determination and design of novel DPP-4 inhibitors [PDF]
Scripta Medica, 2022 Background/Aim: Therapy of diabetes mellitus type 2 includes drugs that act as inhibitors of dipeptidyl peptidase 4 (DPP-4) enzyme. Several DPP-4 inhibitors are marketed today and although they have favourable safety profile and tolerability, they show ...
Rogić Sanja, Gagić Žarko
doaj +1 more source
The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]
, 2013 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core +2 more sources
Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration. [PDF]
, 2015 The gut incretin glucagon-like peptide-1 (GLP-1) and the intestinotropic hormone GLP-2 are released from enteroendocrine L cells in response to ingested nutrients.
Abe, Yosuke +17 more
core +1 more source
Scientific Reports, 2018 The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with pancreatic cancer and acute pancreatitis. Recent meta-analyses have reported conflicting findings.
Lana C. Pinto +4 more
doaj +1 more source
Journal of Research in Medical Sciences, 2022 Background: COVID-19 is responsible for the latest pandemic. Dipeptidyl peptidase-4 (DPP-4) is one of the cellular receptors of interest for coronavirus. The aim of this study was to assess the roles of DPP-4 inhibitors in prognosis of COVID-19 infection
Mohammad Sadidi +5 more
doaj +1 more source
Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study [PDF]
, 2018 Introduction: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods: This was a multicenter
Avogaro Angelo +10 more
core +1 more source
Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. [PDF]
, 2014 peer reviewedPatients with type 2 diabetes mellitus have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis, and about one-third of cirrhotic patients have diabetes.
Scheen, André
core +1 more source
Frontiers in Pharmacology, 2017 Diabetes mellitus has been demonstrated to be closely associated with osteoporosis. Accordingly, hypoglycemic therapy is considered effective in treating metabolic bone disease.
Yinqiu Yang +4 more
doaj +1 more source